RxDoctor Payments Data

Nishant Patel, MD

Family Medicine · Modesto, CANPI 1902399231

Payments from drug & device makers

$897in general payments, 2019–2025

Across 46 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$171
  • Pfizer$135
  • Johnson & Johnson$101
  • GSK$81
  • Scynexis, Inc.$59
  • Novo Nordisk$59
  • plus $292 from 12 others

What the payments were for

  • Food & beverage$897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$897 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$151,806
Medicare patients
252
Services billed
2,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide176$189,255
OzempicSemaglutide126$139,296
JardianceEmpagliflozin69$72,352
EliquisApixaban48$68,698
RybelsusSemaglutide34$50,942
Synjardy XrEmpagliflozin/Metformin Hcl35$40,931
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$40,787
JanuviaSitagliptin Phosphate27$38,506
Repatha SureclickEvolocumab24$24,566
RelistorMethylnaltrexone Bromide11$24,183
MyrbetriqMirabegron18$22,399
Praluent PenAlirocumab16$15,456
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$13,301
Celecoxib123$11,665
Breo ElliptaFluticasone/Vilanterol25$11,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$59$190,237160 claims
Lilly USA, LLCMounjaro$171$189,255176 claims
PfizerEliquis$135$68,69848 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$81$58,03868 claims
MerckJanuvia$18$38,50627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →